FMP
Gain Therapeutics, Inc.
GANX
NASDAQ
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
3.18 USD
0.03 (0.943%)
About
ceo
Mr. Matthias Alder LIC. IUR., LL.M.
sector
Healthcare
industry
Biotechnology
website
https://www.gaintherapeutics.com
exchange
NASDAQ
Description
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded...
CIK
0001819411
ISIN
US36269B1052
CUSIP
36269B105
Address
4800 Montgomery Lane
Phone
301 500 1556
Country
US
Employee
29
IPO Date
Mar 19, 2021
Summary
CIK
0001819411
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
36269B105
ISIN
US36269B1052
Country
US
Price
3.18
Beta
0.43
Volume Avg.
160.33k
Market Cap
51.58M
Shares
-
52-Week
2.0-5.65
DCF
0.7
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.86
P/B
-
Website
https://www.gaintherapeutics.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest GANX News
It looks like there's no news available.
